Show simple item record

dc.contributor.advisorRoy Welsch and Charles Cooney.en_US
dc.contributor.authorEdwards, Emily (Emily Rose)en_US
dc.contributor.otherLeaders for Global Operations Program.en_US
dc.date.accessioned2011-09-27T18:39:07Z
dc.date.available2011-09-27T18:39:07Z
dc.date.copyright2011en_US
dc.date.issued2011en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/66068
dc.descriptionThesis (M.B.A.)--Massachusetts Institute of Technology, Sloan School of Management; and, (S.M.)--Massachusetts Institute of Technology, Engineering Systems Division; in conjunction with the Leaders for Global Operations Program at MIT, 2011.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (p. 50).en_US
dc.description.abstractThis thesis investigates the feasibility of using a complex model with a Monte Carlo simulation model to forecast the financial, personnel, and manufacturing capacity resources needed for biologic drug development. Accurate forecasting is integral across industries in order to make strong longterm, strategic decisions and an area many companies struggle with. The resources required for the development of a biologic drug are especially hard to estimate due to the variability in the time and probability of success of each development phase. However, in the pharmaceutical industry getting products to market faster allows the company more time to recoup the substantial development investments before the patent expires and also potentially has a large impact on a company's market share. For these reasons, Novartis Biologics wanted to develop a simulation model to provide an objective opinion and assist them in their long-range planning. This thesis describes the design, development, and functionalities of the resultant model. During validation runs, the model demonstrated accuracy of greater than 90% when compared against historical data for headcount, number of campaigns, costs, and projects per year. In addition, the model contains Monte Carlo simulation capabilities to allow users to forecast variability and test the sensitivity of the results. This proves the model can be confidently used by project management, operations, and finance to predict their respective future resource needs.en_US
dc.description.statementofresponsibilityby Emily Edwards.en_US
dc.format.extent52 p.en_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.subjectEngineering Systems Division.en_US
dc.subjectLeaders for Global Operations Program.en_US
dc.titleLong range planning of biologics process development and clinical trial material supply processen_US
dc.typeThesisen_US
dc.description.degreeS.M.en_US
dc.description.degreeM.B.A.en_US
dc.contributor.departmentLeaders for Global Operations Program at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Division
dc.contributor.departmentSloan School of Management
dc.identifier.oclc753704952en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record